Anyone who has any doubts about how an influx of cash drives a higher volume of R&D work in biotech should check out BDO's new annual report slicing and dicing the numbers at public biotechs in the U.S.
An innovative new approach, drawing on the disciplines of both medical science and data science, offers the promise of an unprecedented breakthrough in the search for a cure for amyotrophic lateral sclerosis.
Founded and led by hedge fund vet Martin Shkreli, Retrophin has nailed down an agreement to raise $25 million to finance development of a preclinical rare-disease drug and a deal to license a potential autism and schizophrenia compound from an unnamed "major pharmaceutical company." The PIPE financing is expected to close next week.
Bernard Munos, one of the sharpest critics of the drug development industry, takes Big Pharma to task once again on the innovation front after reviewing just what's been approved over the past 12 years.
After all, investors and shareholders responded strongly to Pfizer's animal-health spinoff and nutrition-unit sale--so much so that analysts are calling on CEO Ian Read for more.
While the success rate in developing new disease treatments remains alarmingly low, a cadre of R&D executives from some of the world's biggest drug developers insisted at BIO that they've zeroed in on a number of ways to boost the chance a promising drug will actually reach patients.
Pfizer may be a bit behind schedule, but it's on track to hack its R&D budget to the $6.5-billion-to-$7-billion target laid out in a radical restructuring plan.
Drugmakers and contract researchers keep coming back to the old ways of ushering patients into clinical trials, despite poor results in certain parts of the world and the emergence of new recruitment tools.
E&Y's report today highlighted a growing financial weakness among Big Pharma companies as Big Biotech has begun to flex its growing muscles at the deal table, but everyone expects the multinationals to continue to play the starring role when it comes to the biggest deal stories of the coming year.
Roche isn't likely to imitate its Big Pharma rivals who have been buying back their own shares to keep restive investors happy. Rather, top execs are on the lookout for new technologies that will make the pharma giant an even better competitor.